Pediatric Sepsis Treatment & Management

  • Author: Shankar Santhanam, MD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Apr 11, 2012
 

Approach Considerations

In treating pediatric sepsis, the initial focus should be on stabilization and correction of metabolic, circulatory, and respiratory derangements.[7] Cardiac output may have to be assessed repeatedly. It may be necessary to use multiple peripheral intravenous (IV), intraosseous, or central venous access devices. Frequent sampling of arterial blood is often required. Ongoing reevaluation is essential.

Antimicrobial agents should be given as soon as possible, according to the most likely pathogens. Surgical intervention (eg, draining an abscess, venous access, appendectomy) is occasionally required. Adjunctive therapies may be needed.

Generally, pediatric patients with sepsis should not be fed until gut hypoxia and hypoperfusion have been excluded. Once feeding can safely begin, immune-enhancing nutrition may reduce mortality. Some studies suggest that arginine, omega-3 fatty acids, and messenger RNA (mRNA) may be beneficial.

Next

Initial Resuscitation and Stabilization

Rapid restoration of circulation, tissue perfusion, and oxygen delivery via aggressive volume replacement therapy is the single most important intervention in the acute management of septic shock.[8] Accordingly, fluid resuscitation with crystalloid or colloid parenteral solutions should be initiated immediately.[9] If circulatory derangements do not resolve with 3 IV fluid boluses of 20 mL/kg, vasopressor support should follow.

One study analyzed the outcome of African children who received bolus fluid resuscitation for shock and life-threatening infections and suggested that this practice could be associated with increased mortality in some settings.[3] The study subjects received boluses of 20-40 mL of 5% albumin solution or 0.9% saline solution in quantities of 20-40 mL/kg body weight; the control group received no bolus.

In this study, the 48-hour mortalities were 10.6% (111 of 1050 children) in the albumin-bolus group, 10.5% (110 of 1047 children) in the saline-bolus group, and 7.3% (76 of 1044 children) in the control group; the 4-week mortalities were 12.2%, 12.0%, and 8.7%, respectively.[3] The results suggest that fluid bolus treatment significantly increases the 48-hour mortality in children with severe febrile illness and impaired perfusion who reside in resource-limited settings.

Ventilatory support with supplemental oxygen therapy, aggressive fluid resuscitation and support of cardiac output, maintenance of adequate hemoglobin concentration, correction of physiologic and metabolic derangements, and monitoring of urine output and other end-organ functioning are often vital.

Patients with pediatric sepsis whose circulatory, metabolic, and respiratory derangements are not rapidly corrected should be cared for in an intensive care setting. Transfer should be arranged if the appropriate specialists and intensive care settings are not locally available.

Previous
Next

Empiric Antimicrobial Therapy

Empiric antimicrobial therapy for pediatric sepsis of unclear etiology should be based on the pathogens most frequently encountered in each age group. For example, newborns and infants in the first 6-8 weeks of life should generally receive ampicillin and gentamicin, ampicillin and cefotaxime, or ampicillin and ceftriaxone. Older infants and children most often receive a third-generation cephalosporin (or ampicillin-sulbactam) alone in this situation.

Patients who have indwelling catheters or those who are at high risk for methicillin-resistant S aureus (MRSA) infection may require vancomycin as well. Patients who have fever and neutropenia should receive broad-spectrum coverage with an emphasis on gram-negative rods.

Antimicrobial agents that are used less frequently include caspofungin, micafungin, fluconazole, foscarnet, ganciclovir, valganciclovir, cidofovir, liposomal amphotericin B, itraconazole, and voriconazole. Posaconazole is also used and is approved by the US Food and Drug Administration (FDA) for use in children aged 13 years or older and for prophylaxis of invasive Aspergillus and Candida infections in adult patients who are at high risk as a consequence of severe immunosuppression.

Previous
Next

Adjunctive Therapies

Adjunctive therapies such as inhaled nitric oxide, extracorporeal membrane oxygenation,[10] corticosteroids (eg, dexamethasone or methylprednisolone), pentoxifylline, IV immunoglobulin (IVIg), and various other mediators of the inflammatory response may be needed.

In cases of refractory shock, additional adjunctive therapies (eg, terlipressin) have shown potential benefit in initial trials.[11] Further clinical studies are required, but the risks of the drug may be outweighed by its benefits in certain circumstances.

Bovine lactoferrin supplementation (alone or in combination with the probiotic Lactobacillus rhamnosus GG) for very low birth weight neonates reduces the incidence of a first episode of late-onset sepsis.[12, 13, 14] Similarly, pentoxifylline adjunctive therapy may reduce mortality from late-onset sepsis.[15] Studies of other such interventions are under way.

Withdrawal of drotrecogin alfa

Drotrecogin alfa, a recombinant human-activated protein C indicated for reduction of mortality in adults with severe sepsis, was approved by the FDA for treatment of sepsis in adults, but enrollment in its phase III clinical trial for use in pediatric patients was halted in March 2005 after it was determined that the drug was unlikely to demonstrate improvement over placebo.

The drug was withdrawn from the worldwide market on October 25, 2011, after the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS)-SHOCK clinical trial failed to demonstrate a statistically significant reduction in 28-day all-cause mortality in patients with severe sepsis and septic shock. Trial results documented a 28-day all-cause mortality of 26.4% in patients treated with activated drotrecogin alfa, compared with 24.2% in the placebo group.[16, 17, 18, 19]

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Shankar Santhanam, MD  Consulting Staff, Department of Emergency Medicine, Emergency Medical Associates; Consulting Staff, Department of Family Medicine, Capital Health Systems

Shankar Santhanam, MD is a member of the following medical societies: American Academy of Family Physicians and American Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: Novartis Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

Itzhak Brook, MD, MSc Professor, Department of Pediatrics, Georgetown University School of Medicine

Itzhak Brook, MD, MSc is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Armed Forces Infectious Diseases Society, Association of Military Surgeons of the US, Infectious Diseases Society of America, International Immunocompromised Host Society, International Society for Infectious Diseases,

Mark R Schleiss, MD American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota Medical School

Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. Jan 2005;6(1):2-8. [Medline].

  2. Greenhow TL, Hung YY, Herz AM. Changing epidemiology of bacteremia in infants aged 1 week to 3 months. Pediatrics. Mar 2012;129(3):e590-6. [Medline].

  3. Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med. Jun 30 2011;364(26):2483-95. [Medline].

  4. Myburgh JA. Fluid resuscitation in acute illness--time to reappraise the basics. N Engl J Med. Jun 30 2011;364(26):2543-4. [Medline].

  5. Mancini N, Carletti S, Ghidoli N, Cichero P, Burioni R, Clementi M. The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev. Jan 2010;23(1):235-51. [Medline]. [Full Text].

  6. Rajani AK, Philip AGS. Diagnostic Tests in Neonatology: Evaluation and Interpretation Using Sepsis as an Example. NeoReviews. Jul 2011;12(7):e368-e373.

  7. [Guideline] Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. Jan 2008;34(1):17-60. [Medline]. [Full Text].

  8. [Best Evidence] [Guideline] Yager P, Noviski N. Shock. Pediatr Rev. Aug 2010;31(8):311-8; quiz 319. [Medline].

  9. Larsen GY, Mecham N, Greenberg R. An emergency department septic shock protocol and care guideline for children initiated at triage. Pediatrics. Jun 2011;127(6):e1585-92. [Medline].

  10. Skinner SC, Iocono JA, Ballard HO, Turner MD, Ward AN, Davenport DL, et al. Improved survival in venovenous vs venoarterial extracorporeal membrane oxygenation for pediatric noncardiac sepsis patients: a study of the Extracorporeal Life Support Organization registry. J Pediatr Surg. Jan 2012;47(1):63-7. [Medline].

  11. Rodríguez-Núñez A, López-Herce J, Gil-Antón J, Hernández A, Rey C. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care. Feb 2006;10(1):R20. [Medline]. [Full Text].

  12. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. Oct 7 2009;302(13):1421-8. [Medline].

  13. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. Oct 5 2011;CD007137. [Medline].

  14. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics. Jan 2012;129(1):116-23. [Medline].

  15. Haque KN, Pammi M. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev. Oct 5 2011;CD004205. [Medline].

  16. FDA Safety Alert. Xigris [drotrecogin alfa (activated)]: Market Withdrawal - Failure to Show Survival Benefit. US Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm277143.htm. Accessed October 26, 2011.

  17. PR Newswire. Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results. Lilly. Available at https://investor.lilly.com/releasedetail2.cfm?ReleaseID=617602. Accessed October 26, 2011.

  18. Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. Jan 2004;113(1 Pt 1):7-17. [Medline].

  19. Weiss KD. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. Jan 2004;113(1 Pt 1):134. [Medline].

Previous
Next
 
Pathogenesis of sepsis and multiple organ dysfunction syndrome (MODS).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.